Today's Pharma Pulse
CMS to launch Medicare GLP‑1 Bridge program with $50 monthly copay for obesity drugs
The Centers for Medicare & Medicaid Services will start a short‑term demonstration on July 1 2026 offering eligible Part D beneficiaries a flat $50 monthly copay for three branded GLP‑1 obesity treatments. The program runs through December 31 2027 and aims to gather utilization data ahead of potential broader policy decisions.
Motif Neurotech Receives FDA IDE Approval to Initiate RESONATE Trial of Motif XCS System in Treatment-Resistant Depression
Motif Neurotech has secured FDA Investigational Device Exemption (IDE) to launch the RESONATE early feasibility study of its Motif XCS System in patients with treatment‑resistant depression who have failed at least two medications. The trial will monitor 12‑month safety, symptom reduction, quality of life, anxiety and cognitive function using standard clinical scales. The XCS device is a small, wirelessly powered implant placed over a validated depression target via a roughly 20‑minute outpatient procedure, allowing continuous brain‑signal monitoring to tailor therapy. Successful outcomes could position the system as a first‑in‑class therapeutic brain‑computer interface for psychiatric care.
Unverified Tips Can Mislead: False Compass Data
Interesting side note on today's disappointing $CMPX results: Yesterday, I received a message on Signal from someone claiming to be a Compass employee. He gave me the purported tovecimig PFS and OS data. I didn't do anything with the supposedly material...
India Busts Massive Counterfeit Food and Drug Operation
🚨 INDIA EATING POISON 🚨 Delhi - Fake toothpaste factory: 1,800 filled tubes, 10,000 empty tubes, 1,200 packed units and 130kg of raw material of Sensodyne toothpaste. - Fake Eno sachets: 1 lakh. - Fake Nescafé sachets: 50,000. Ayodhya - 500 cartons of fake Fortune oil...
GSK/Tesaro Claim Denied in Jemperli Lawsuit with AnaptysBio
A Delaware court rejected GSK and its Tesaro unit's attempt to terminate the 2014 licensing agreement with AnaptysBio, preserving the existing royalty rate for the PD‑1 cancer drug Jemperli. The ruling affirms that AnaptysBio has not breached the contract, while...
Fathom Therapeutics Secures $47M Series A for AI‑Physics Drug Discovery
Exclusive: Fathom Therapeutics, formerly Atommap, has raised a $47M Series A, building a pipeline with its strategy of blending AI and physics approaches to drug discovery: https://t.co/iAlmJwCQK7
CRISPR Therapy Cuts Swelling Attacks 87%, 60% Attack‑Free
$NTLA Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial Attack rates dropped 87%, relative to placebo. Just over 60% were entirely attack-free over the period, compared to 11% for the placebo patients. https://t.co/ljPC7Lww0D via @Jasonmmast
Cell, Gene And Specialty Drug Costs Intensify For Health Plans
A new Pharmaceutical Strategies Group survey of 228 benefits executives shows 43% of health plans rank controlling specialty drug costs as their top priority, ahead of total cost of care. Specialty medicines now consume more than half of prescription spending,...
NTLA's Attack Metrics Fall Short of Expectations
$NTLA 87% attack reduction and only 62% attack free rate. Attack free rate especially widely missed the bar set ahead of time by @GeneInvesting. Legitimately worse than I expected. https://t.co/wmNFYfsQSj
Oruka's Long-Acting Psoriasis Drug Achieves 63% PASI‑100
$ORKA Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study 63% PASI 100 score at 16 weeks, very strong data. https://t.co/RJxnbuU0e3 via me
STAT+: Oruka’s Long-Acting Psoriasis Therapy Posts Strong Results in Mid-Stage Study
Oruka Therapeutics reported that its long‑acting injectable, ORKA‑001, achieved complete skin clearance in 63% of plaque‑psoriasis patients during a mid‑stage trial. The data suggest the drug can be administered just once per year, a stark contrast to current biologics that...
Veradermics' Hair Loss Drug Clears Late-Stage Trial
Ok, here we go... $MANE Veradermics' hair loss drug succeeds in late-stage trial. A report from @ADeAngelis_bio https://t.co/jtSB36sPGO
STAT+: Veradermics’ Hair Loss Drug Succeeds in Late-Stage Trial
Veradermics announced that its oral hair loss drug VDPHL01 met primary endpoints in a Phase III trial. Over six months, participants taking the pill grew 30‑33 hairs per square centimeter versus seven in the placebo group. Patient‑reported improvement reached 79‑86%, and...
Zepbound’s and Ozempic’s Greatest Benefit May Be Their Anti-Inflammatory Power
GLP‑1 drugs such as Ozempic and Zepbound are gaining recognition for anti‑inflammatory effects that go beyond weight loss and glucose control. Clinical data show semaglutide reduces C‑reactive protein by about 40% independent of weight loss and improves liver inflammation in...
Ascletis Completes Enrollment in U.S. Phase‑II Trial of Oral GLP‑1 Agonist ASC30
Ascletis Pharma announced that its 13‑week U.S. Phase‑II trial of ASC30, an oral small‑molecule GLP‑1 receptor agonist for type‑2 diabetes, has enrolled 100 participants. The company expects topline results in the third quarter of 2026, a milestone that could reshape...
Can We Truly Deliver Gene Therapies to Patients Without Solving the Cost and Scale Challenges of AAV Production?
Gene‑therapy developers are confronting a manufacturing bottleneck as adeno‑associated virus (AAV) vectors must be produced at commercial scale. FUJIFILM Biotechnologies proposes 2,000‑liter single‑use bioreactors combined with an integrated CDMO model to boost yield, cut cost per dose, and preserve product...
AstraZeneca Reports FDA Approval of Saphnelo for Systemic Lupus Erythematosus (SLE)
The U.S. Food and Drug Administration has granted approval for AstraZeneca’s Saphnelo autoinjector (anifrolumab, 120 mg weekly) for adult patients with systemic lupus erythematosus (SLE) when used alongside standard of care. The decision follows the Phase III TULIP‑SC trial, which enrolled 367...
Novartis Secures Pair of Regulatory Wins for Skin Disease and Malaria Treatments
Novartis won two regulatory milestones: the European Commission approved its oral BTK inhibitor Rhapsido for adults with chronic spontaneous urticaria who have failed antihistamines, and the World Health Organization granted prequalification to Coartem Baby, an artemether‑lumefantrine formulation for infants weighing 2‑5 kg....
Longevity Medicine’s New Vanguard: 11 Innovators Poised to Drive an $8 Trillion Market
Business Insider unveiled its 2026 Rising Stars of Longevity, naming 11 innovators whose AI‑driven diagnostics, biotech breakthroughs and gerotherapeutics aim to capture a market expected to grow to $8 trillion by 2030. The list, vetted by experts like Andrea Maier and...
Key Insights Await From Tovecimig Companion-002 Data
$CMPX data from Companion-002 study of tovecimig coming before 8am ET today. What to look out for, via @ByMadeleineA -> https://t.co/6IDCqMyNPE
Reviewing the Inability of Anti-Amyloid Immunotherapies to Affect Alzheimer's Disease
A recent Cochrane meta‑analysis of ten anti‑amyloid monoclonal antibodies—including aducanumab, lecanemab and donanemab—shows only trivial cognitive gains and modest functional improvement in patients with mild Alzheimer’s disease, despite clear plaque clearance. The studies also reveal an elevated risk of amyloid‑related...
New NIHR-Funded TRC for Parkinson’s Disease
The National Institute for Health and Care Research (NIHR) has launched the Parkinson’s disease Translational Research Collaboration (PD‑TRC), the first of eight UK TRCs dedicated to Parkinson’s. Backed by NIHR and four major charities, the hub links 17 centres of...
Lilly Falls on Slower Start for Foundayo versus Wegovy
Eli Lilly’s oral GLP‑1 agonist Foundayo launched in early April with modest uptake, recording 1,390 prescriptions in week 1 and 3,707 in week 2, far below Novo Nordisk’s oral Wegovy, which logged over 3,000 fills in its first days and 18,410 in the second...
Sun Pharma to Acquire Organon for $11.75 B, Boosting Women’s Health and Biosimilars
Sun Pharmaceutical Industries announced an all‑cash deal to acquire Organon & Co. for $14 per share, valuing the U.S. firm at $11.75 billion. The merger will lift Sun Pharma into the top‑25 global drugmakers, give it a top‑3 position in women’s...
How Can Pharma Prices Be Reduced for Americans Without Impacting Innovation?
President Trump announced a sweeping plan to impose 100% tariffs on branded pharmaceuticals, while offering exemptions to companies that sign most‑favored‑nation (MFN) agreements. The policy is framed as a way to force lower drug prices for American patients and to...
UK Biotech Could Be Bound for Recovery, BIA Report Reveals
UK biotech venture financing rebounded in Q1 2026, with total equity raised climbing 18% to £552 m ($746 m). Venture‑capital inflows also rose 17% to £516 m ($699 m), and 25 companies secured funding, up from 15 a year earlier. While public‑market activity stayed flat—no...
New Bird Flu Vaccine Shows Promise Against Multiple H5N1 Strains
University of Nebraska–Lincoln researchers have unveiled a nanodisc‑based vaccine that protects mice and dairy calves from multiple H5N1 bird‑flu strains. The platform uses a prime‑boost regimen combining intramuscular and intranasal delivery to generate systemic and mucosal immunity. Preclinical trials showed...
The WHO Is Building a Supranational Vaccine Authorization Mechanism
The World Health Organization’s Emergency Use Listing (EUL) has evolved from a temporary pandemic tool into a supranational framework that can shape national vaccine approvals. Israel’s Ministry of Health used the EUL to fast‑track the nOPV2 polio vaccine, effectively allowing...
BrioHealth Secures FDA Approval to Launch BrioVAD System Trial
BrioHealth Solutions received conditional FDA approval to launch the Brio4Kids trial, testing its BrioVAD left ventricular assist device in children with advanced heart failure. Enrollment in the U.S. study is slated for mid‑2026, with initial data expected in the fourth...
Kyowa Kirin and Kura Initiate Phase II Trial of Ziftomenib for AML
Kyowa Kirin and Kura Oncology have opened a Japanese Phase II registrational study of the oral menin inhibitor ziftomenib in adults with relapsed or refractory NPM1‑mutated acute myeloid leukaemia. The single‑arm, open‑label trial will measure a composite complete remission rate (CR + CRh) as...
Review Questions Benefits of Anti-Amyloid Alzheimer’s Drugs
A Cochrane review of 17 clinical trials involving 20,342 patients with early Alzheimer’s disease found that anti‑amyloid drugs provide no clinically meaningful benefit on cognitive decline or dementia severity. The analysis also highlighted an increased risk of brain swelling and...
Sanofi Reports the CHMP Positive Opinion for Cenrifki (Tolebrutinib) to Treat Non-Relapsing SPMS
Sanofi’s oral BTK inhibitor Cenrifki (tolebrutinib) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating secondary progressive multiple sclerosis (SPMS) without relapses in the past two years. The recommendation is...
FDA Approves Weekly Self‑Injectable Saphnelo for Lupus
#AZN Saphnelo for treating systemic lupus erythematosus, approved by US FDA for self-administration via a once a week autoinjector Pen.
Tesaro's Breach Claim Dismissed, Jemperli Licence Fight Persists
Looks like #GSK subsidiary TESARO Inc., has had a "claim for anticipatory breach" against AnaptysBio kicked out by Delaware Chancery Court. Principal contract dispute still ongoing though around Jemperli (Dostarlimab) licence agreement.
AI in Single-Cell Analysis: Solving the Interpretation Gap
Single‑cell omics drives drug discovery but interpreting cell‑state annotations remains a bottleneck. Nygen Analytics introduced CyteType, an AI‑augmented platform that adds a traceable interpretation layer to existing pipelines, converting raw clusters into biologically meaningful labels. By combining marker‑gene analysis, literature...
Novartis’ Itvisma Receives the CHMP Positive Opinion for Spinal Muscular Atrophy
Novartis’ gene‑replacement therapy Itvisma (onasemnogene abeparvovec) received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for treating patients aged two years and older with 5q spinal muscular atrophy (SMA). The recommendation is...
Evonik: €80m for Biopharma CDMO Capacity in Slovakia
Evonik Industries is allocating roughly €80 million (about $87 million) to expand its fermentation plant in Slovenská Ľupča, Slovakia. The investment adds downstream capacity for pharmaceutical active ingredients and creates around 50 new jobs. The site, already a biotech hub producing spider‑silk protein...
What Your CD3 T Cell Engager Is Missing
CD3 T‑cell engagers have become a cornerstone of bispecific immunotherapy, linking T cells to cancer cells via the CD3 receptor. The article argues that despite their success, these molecules often provide only the primary activation signal, neglecting a critical secondary...
Swedish Clinic Finds Limited Eligibility for New Alzheimer Drugs
Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic https://t.co/H3TgYvgVSk
The Cure for Death Means Billionaires Will Live Forever—And Be Rich Forever
U.S. billionaires enjoy a dramatically higher life expectancy, with 20% living past 80 compared to just 3.8% of the general population. Their longevity stems from access to premium healthcare, personal trainers, and cutting‑edge nutrition. Meanwhile, leaders like Putin and Xi...
In the Land of the Unblind: Are Psychedelics Really Better than Antidepressants?
Recent meta‑analysis comparing psychedelic‑assisted therapy (PAT) with open‑label antidepressant trials finds no clinically important difference in depression outcomes. While early PAT studies suggested larger effects, the analysis shows that functional unblinding limits any advantage, and open‑label antidepressants marginally outperform blinded...
Free Radicals Podcast (Longevity / Biotech Oriented)
Kexin Huang, the a16z‑backed founder of Pho, argues that biology is entering an "Agentic Biology" era where AI agents orchestrate research rather than merely analyze data. His Integrated Biology Environment (IBE), embodied in the Biomni platform, acts like an IDE...
Free Radicals Podcast (Longevity / Biotech Oriented)
Nathan Cheng argues that aging remains untreated due to a coordination failure rooted in cultural "deathism," despite roughly 100,000 daily deaths from age‑related diseases. He highlights a stark $5 B versus $100 B+ funding gap between longevity and cancer research, underscoring the...
Secretome-Mediated Antimicrobial and Immunomodulatory Activity of Lactobacillus Johnsonii Against Multidrug-Resistant Enteroaggregative Escherichia Coli
Researchers evaluated Lactobacillus johnsonii as a probiotic against a multidrug‑resistant enteroaggregative E. coli (EAEC) strain. The bacterium showed strong gastrointestinal tolerance, high auto‑aggregation (80 % at 4 h), and secretome‑driven inhibition of EAEC growth and biofilm formation, surpassing gentamicin. It also reduced...
Mapping Genomic Landscape of Multiple Myeloma Precursors
Genomic landscape of multiple myeloma and its precursor conditions [May 21, 2025] Jean-Baptiste Alberge et al. @IrenemGhobrial @NatureGenet https://t.co/DDWGRrpI4Y #mmsm #PrecisionMedicine #cagenome https://t.co/X0OPLHNkdG
Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/d0JNE6pb5x
Amazon Launches GLP‑1 Weight‑Loss Program, Targeting $100 B Market
Amazon announced a GLP‑1‑focused weight‑management program through its One Medical platform, letting patients order injectable and oral GLP‑1 drugs with same‑day delivery. The move pits the tech giant against pharma leaders Eli Lilly and Novo Nordisk as the market races toward a...
Abbott Elevates Jenil Sheth to Head of Marketing, Boosting Healthcare Brand Strategy
Abbott has promoted Jenil Sheth to Head of Marketing, tasking him with steering brand and growth programs across its therapeutic and consumer health portfolios. Sheth brings more than eight years at Abbott and a deep pharmaceutical background, positioning the company...
Uridine Shields Neurons by Activating Mitochondrial K⁺ Channel
The Protective Effect of Uridine in a Rotenone-Induced Model of Parkinson’s Disease: The Role of the Mitochondrial ATP-Dependent Potassium Channel https://t.co/jBlSlgedWo
MIT Unveils Injectable “Mini‑liver” Constructs to Bridge Transplant Waitlist
MIT scientists have engineered injectable hydrogel microsphere “mini‑livers” that sustain liver function in animal models for over two months, aiming to reduce dependence on donor organs. The breakthrough, published in Cell Biomaterials, could reshape treatment for thousands on transplant waiting...
FDA Approves Sanofi's Tzield to Delay Type 1 Diabetes in Children as Young as One Year
Sanofi’s teplizumab‑mzwv, sold as Tzield, received FDA approval to expand its use to children from age one, aiming to postpone the onset of stage 3 type 1 diabetes. The decision follows the PETITE‑T1D phase‑4 trial, which showed 89.6% of participants remained free...